Overview
Ibogaine is a psychoactive monoterpenoid indole alkaloid that occurs in the root bark of Tabernanthe iboga, a Central African shrub associated with Bwiti religious and healing traditions.[1][2] In contemporary biomedical discussion, ibogaine is usually classified as an investigational compound rather than an approved medication, because no ibogaine product is approved by the U.S. Food and Drug Administration for any indication.
Ibogaine is often grouped with psychedelics, but its pharmacology is broader than that of classic serotonergic psychedelics such as psilocybin or LSD. Users and researchers frequently describe its subjective effects as oneirogenic, meaning dream-like or visionary, because ibogaine experiences commonly involve prolonged waking imagery, autobiographical review, and altered self-reflection.
For a broader introduction to the substance, see What Is Ibogaine?, and for treatment-focused context, see What Is Ibogaine Treatment?.
Classification by Category
Ibogaine has several overlapping classifications because legal systems, pharmacology, chemistry, and clinical research use different classification frameworks.[1]
- Chemical class: Ibogaine is an indole alkaloid and is commonly described as a monoterpenoid or monoterpene indole alkaloid.[1][2]
- Pharmacologic class: Ibogaine is an atypical psychedelic or oneirogen with activity across NMDA, nicotinic acetylcholine, opioid, serotonin, dopamine, sigma, and cardiac ion-channel systems.[3]
- Therapeutic-development class: Ibogaine is an investigational anti-addiction compound studied mainly for opioid withdrawal and substance use disorders.[4]
- U.S. legal class: Ibogaine is listed in Schedule I under 21 CFR 1308.11(d) as a hallucinogenic substance with DEA code 7260.[5]
- International legal status: Ibogaine is not uniformly regulated worldwide, and national rules vary from controlled-drug prohibition to prescription-only status, partial decriminalization, or practical non-scheduling.[6]
Because these categories measure different things, ibogaine can simultaneously be a plant-derived alkaloid, a hallucinogenic Schedule I substance, a psychedelic-like oneirogen, and a research candidate for addiction treatment.[1][5]
United States Legal Classification
Under U.S. federal law, ibogaine is a Schedule I controlled substance in the hallucinogenic-substances subsection of the Controlled Substances Act regulations.[5] Schedule I status means the federal government classifies the substance as having a high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision.[5]
This legal classification is distinct from a full scientific determination that ibogaine lacks therapeutic potential, because Schedule I status is a regulatory category that can persist despite ongoing research interest. The classification has contributed to research barriers, including special registration requirements, controlled-substance storage rules, added regulatory review, and increased trial costs.
Ibogaine treatment outside an authorized clinical trial is not legally available in the United States under federal law.[5] Some state or local policies have addressed natural psychedelics or enforcement priorities, but these policies do not remove federal Schedule I restrictions. For location-specific discussion, see Ibogaine Treatment in Florida and Ibogaine Treatment in Colorado.
Pharmacologic Mechanisms
Ibogaine is pharmacologically unusual because it interacts with multiple receptor and transporter systems rather than acting through a single dominant target. It has been reported to interact with NMDA glutamate receptors, nicotinic acetylcholine receptors, opioid receptors, serotonin transporters, sigma receptors, dopamine-related reward circuitry, and cardiac potassium channels.[3]
After oral administration, ibogaine is metabolized to noribogaine, a longer-lasting active metabolite that is thought to contribute to prolonged anti-withdrawal, anti-craving, and mood-related effects. Noribogaine has serotonin-reuptake-inhibiting properties and opioid-receptor activity, which may help explain why ibogaine differs from classic serotonergic psychedelics.
Ibogaine also affects cardiac repolarization by blocking hERG potassium channels, a mechanism associated with QT-interval prolongation and potentially dangerous ventricular arrhythmias.[3] This cardiac mechanism is central to ibogaine’s medical-risk profile and helps explain why safety screening and monitoring are repeatedly emphasized in clinical and toxicology discussions.[3]
Clinical Evidence and Research Status
The strongest clinical signal for ibogaine is its reported ability to reduce acute opioid withdrawal symptoms, but the evidence base remains dominated by case series, open-label studies, observational follow-up, and retrospective reports rather than large randomized controlled trials.[4][7][8]
In 1999, Alper and colleagues published a case series of 33 people treated with ibogaine for acute opioid withdrawal, and the authors reported marked reductions in withdrawal signs in many participants.[4] The study was uncontrolled, involved heterogeneous treatment conditions, and could not establish efficacy compared with standard treatments such as buprenorphine or methadone.[4]
Animal research has generally supported anti-addictive effects across opioid, stimulant, nicotine, and alcohol-related models, but a systematic review concluded that study quality and translational uncertainty limit direct clinical conclusions.[9] Observational studies in New Zealand and Mexico have reported reductions in opioid use, craving, and withdrawal among some participants, but relapse and variable outcomes remain common.[7][8]
Because ibogaine has not been validated by large, definitive randomized trials, it should not be described as an established cure for opioid use disorder or any other substance use disorder.[7] For a condition-specific review, see Ibogaine for Opioid Addiction.[7]
Safety Risks and Contraindications
Ibogaine’s most important safety concern is cardiac toxicity, particularly QT-interval prolongation that can increase the risk of torsades de pointes, ventricular tachycardia, and sudden death.[3] The cardiac risk is related in part to hERG potassium-channel blockade by ibogaine and potentially by noribogaine.[3]
A forensic review by Alper, Stajić, and Gill analyzed deaths temporally associated with ibogaine ingestion and found that many cases involved factors such as cardiovascular disease, substance co-use, electrolyte abnormalities, or inadequate medical screening.[10] The review did not identify a single universal mechanism for all deaths, but it supported the need for careful exclusion criteria and medical monitoring.[10]
Common acute adverse effects include nausea, vomiting, ataxia, tremor, insomnia, anxiety, confusion, and prolonged altered perception. Vomiting and diarrhea can worsen dehydration and electrolyte imbalance, which may further increase cardiac risk.[3]
High-risk situations include known heart disease, prolonged QT interval, arrhythmia history, electrolyte abnormalities, severe liver disease, pregnancy, active psychosis, mania risk, polysubstance use, and use of medications that prolong QT or affect CYP2D6 metabolism.[3] Potentially hazardous combinations include methadone, stimulants, cocaine, some antidepressants, antipsychotics, macrolide antibiotics, fluoroquinolones, and other QT-prolonging drugs.[3]
International Regulation
Ibogaine is not regulated uniformly across countries, and legal availability should not be interpreted as proof of medical approval or safety.[6] Some countries regulate ibogaine as a prescription or controlled medicine, while others prohibit it, leave it unscheduled, or allow treatment centers to operate under less clearly defined legal frameworks.[6]
Canada has treated ibogaine as a prescription drug rather than as an unregulated natural product, and New Zealand has permitted some prescription-based use and observational research under its medicines framework.[7] Mexico has become a major destination for ibogaine treatment because ibogaine is not scheduled in the same way as in the United States, but clinic quality and medical oversight vary widely.[6][8]
People considering treatment abroad face medical-tourism risks, including inconsistent screening, variable emergency readiness, uncertain drug purity, and limited follow-up after returning home.[6][10] For more location-specific information, see Ibogaine Legality by Country, Ibogaine Treatment in Mexico, and Ibogaine Treatment Centers.[6]
Emerging Research Beyond Addiction
Recent research has expanded interest in ibogaine beyond substance use disorders into traumatic brain injury, post-traumatic stress symptoms, depression, and anxiety.[11] A 2024 open-label Nature Medicine study evaluated magnesium-assisted ibogaine therapy in 30 male U.S. Special Operations Forces veterans with traumatic brain injury histories and neuropsychiatric symptoms.[11]
The study reported improvements in disability, PTSD, depression, and anxiety measures, and no serious adverse events were reported in that carefully screened and monitored cohort.[11] The study was not randomized or placebo-controlled, so it cannot establish that ibogaine caused the improvements or that the findings apply to broader populations.[11]
This research has increased interest in magnesium-supported protocols and veteran mental-health applications, but it does not remove the known cardiac and drug-interaction concerns associated with ibogaine.[3][11] For related pages, see Ibogaine for TBI and Ibogaine for PTSD.[11]
Comparison With Established Treatments
Ibogaine differs from standard medications for opioid use disorder because it is usually promoted as a short-course or single-session intervention, whereas methadone and buprenorphine are evidence-based maintenance treatments used in continuing care.[7] The clinical evidence for methadone and buprenorphine is much stronger than the clinical evidence for ibogaine, particularly for retention in care and reduction of overdose mortality.
Ibogaine may reduce acute opioid withdrawal in some observational settings, but it has not been proven to provide durable relapse prevention comparable to approved medications.[4][7][8] It also carries cardiac risks that require a level of screening and monitoring not associated with most conventional detoxification approaches.[3][10]
Ibogaine should therefore be described as promising but unproven, rather than as a replacement for approved opioid-use-disorder treatment.[7] Additional context on practical access, costs, and treatment models is available in Ibogaine Treatment, Ibogaine Treatment Cost, and Ibogaine Therapy.
Future Outlook
Future research priorities include randomized controlled trials, dose-finding studies, standardized cardiac monitoring, pharmacokinetic research on noribogaine, long-term relapse follow-up, and clearer adverse-event reporting.[3][7]
Research interest also includes ibogaine analogs and related compounds that may retain anti-addictive or neuroplasticity-related effects while reducing hallucination, arrhythmia risk, or other toxicities.[9] Noribogaine, 18-methoxycoronaridine, and other iboga-inspired compounds have been discussed as possible development paths because ibogaine itself presents major safety and regulatory challenges.
Whether ibogaine becomes an accepted medicine will depend on whether controlled trials can demonstrate that benefits outweigh risks under pharmaceutical-grade manufacturing, rigorous screening, continuous cardiac monitoring, and structured aftercare.[3][10]